Faecal calprotectin: A noninvasive diagnostic tool and marker of severity in pouchitis

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 3, 2008, Pages 174-179

  Johnson, Matt W ^a   Maestranzi, Susan ^b   Duffy, Audrey M ^b   Dewar, David H ^c   Forbes, Alastair ^d   Bjarnason, Ingvar ^b   Sherwood, Roy A ^b   Ciclitira, Paul ^c   Nicholls, John R ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Diagnostic tool; Faecal calprotectin; Inflammatory bowel disease; Inflammatory marker; Pouchitis

Indexed keywords

CALGRANULIN;

ADULT; ARTICLE; COLON POLYPOSIS; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HUMAN; ILEITIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; PROCTOCOLECTOMY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

ADENOMATOUS POLYPOSIS COLI; ADULT; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; DIAGNOSIS, DIFFERENTIAL; ENDOSCOPY, GASTROINTESTINAL; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; POUCHITIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 39849108182     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282f1c9a7     Document Type: Article

References (33)

1. Moskowitz RL, Shepherd NA, Nicholls RJ. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis 1986; 1:167-174.
2. Shepherd NA, Jass JR, Duval I, Moskowitz RL, Nicholls RJ, Morson BC. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol 1987; 40:601-607.
3. Clohessy PA, Golden BE. Calprotectin-mediated zinc chelation as a biostatic mechanism in host defence. Scand J Immunol 1995; 42:551-556.
4. Sohnle PG, Hahn BL, Santhanagopalan V. Inhibition of candida albicans growth by calprotectin in the absence of direct contact with the organisms. J Infect Dis 1996; 174:1369-1372.
5. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58:176-180.
6. Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999; 45:362-366.
7. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119:15-22.
8. Hatasaka HH, Sharp HT, Dowling DD, Teahon K, Peterson CM. Laparoscopic tubal ligation in a minimally invasive surgical unit under local anesthesia compared to a conventional operating room approach under general anesthesia. J Laparoendosc Adv Surg Tech A 1997; 7:295-299.
9. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27:793-798.
10. Kristinsson J, Roseth A, Fagerhol MK, Aadland E, Schjonsby H, Bormer OP, et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 1998; 41:316-321.
11. Loftus B, Loh LC, Curran B, Henry K, Leader M. Mac387: its non-specificity as a tumour marker or marker of histiocytes. Histopathology 1991; 19:251-255.
12. Dale I, Brandtzaeg P. Expression of the epithelial L1 antigen as an immunohistochemical marker of squamous cell carcinoma of the lung. Histopathology 1989; 14:493-502.
13. Tungekar MF, Heryet A, Gatter KC. The L1 antigen and squamous metaplasia in the bladder. Histopathology 1991; 19:245-250.
14. Meling TR, Aabakken L, Roseth A, Osnes M. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1996; 31:339-344.
15. Ton H, Brandsnes O, Dale S, Holtlund J, Skuibina E, Schjonsby H, Johne B. Improved assay for fecal calprotectin. Clin Chim Acta 2000; 292:41-54.
16. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc 1994; 69:409-415.
17. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32:174-178.
18. Modigliani R. Endoscopic management of inflammatory bowel disease. Am J Gastroenterol 1994; 89 (8 Suppl):S53-S65.
19. Saverymuttu SH, Camilleri M, Rees H, Lavender JP, Hodgson HJ, Chadwick VS. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 1986; 90 (5 Pt 1):1121-1128.
20. Saverymuttu SH, Peters AM, Reavy HJ, Lavender JP. Measurement of granulocyte migration and accumulation in inflammation in man. Clin Exp Immunol 1983; 52:607-612.
21. Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 32:171-177.
22. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450-460.
23. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33:14-22.
24. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54:364-368.
25. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004; 39:1017-1020.
26. Parsi MA, Shen B, Achkar JP, Remzi FF, Goldblum JR, Boone J, et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004; 126:1280-1286.
27. Johnson MW, Maestranzi S, Dewar DH, Forbes A, Ciclitira PJ, Nicholls RJ. Faecal M2-pyruvate kinase; a novel non-invasive marker of ileal pouch inflammation. Gut 2006; 55:A116-A117.
28. Johnson MW, Dewar DH, Ciclitira P, Forbes A, Nicholls RJ, Bjarnason I. Use of fecal lactoferrin to diagnose irritable pouch syndrome: a word of caution. Gastroenterology 2004; 127:1647-1648.
29. Thomas P, Rihani H, Roseth A, Sigthorsson G, Price A, Nicholls RJ, Bjarnason I. Assessment of ileal pouch inflammation by single-stool calprotectin assay. Dis Colon Rectum 2000; 43:214-220.
30. Harvey RF, Bradshaw MJ. Measuring Crohn's disease activity. Lancet 1980; 1:1134-1135.
31. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47:506-513.
32. Das P, Johnson MW, Tekkis PP, Nicholls RJ. Risk of dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. Colorectal Dis 2007; 9:15-27.
33. Johnson MW, Dewar DH, Forbes A, Ciclitira PJ, Nicholls RJ Nutritional deficiency in ileal pouch patients: is it related to histology? Gut 2005; 54:A235.